The drug trastuzumab (Herceptin; recombinant humanized IgG1 monoclonal antibody) has demonstrated high affinity against the extracellular domain of HER2, resulting in inhibition of cancer cells growth and proliferation, and increased survival in the breast and gastric cancer patients [107]. Here, ERBB2 is linked to cancer.